Next Article in Journal
The Genomic Diversity and Phylogenetic Relationship in the Family Iridoviridae
Next Article in Special Issue
Combination Chemotherapy for Influenza
Previous Article in Journal
The HTLV-1 Virological Synapse
Article Menu

Export Article

Open AccessReview
Viruses 2010, 2(7), 1448-1457; doi:10.3390/v2071448

siRNA for Influenza Therapy

Department of Biochemistry and Molecular Biology, University of South Alabama, College of Medicine, MSB 2370, 307 University Boulevard, Mobile, AL 36688-0002, USA
Received: 1 June 2010 / Revised: 5 July 2010 / Accepted: 7 July 2010 / Published: 9 July 2010
(This article belongs to the Special Issue Antivirals Against Influenza)
View Full-Text   |   Download PDF [102 KB, uploaded 12 May 2015]   |  


Influenza virus is one of the most prevalent and ancient infections in humans. About a fifth of world's population is infected by influenza virus annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. In the US alone, influenza outbreaks lead to roughly 30,000 deaths each year. Current vaccines and anti-influenza drugs are of limited use due to high mutation rate of the virus and side effects. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. The siRNAs outperform traditional small molecule antivirals in a number of areas, such as ease of design, modest cost, and fast turnaround. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism, which is reviewed here.
Keywords: influenza virus; short interfering RNA; RNA interference; antiviral influenza virus; short interfering RNA; RNA interference; antiviral

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Barik, S. siRNA for Influenza Therapy. Viruses 2010, 2, 1448-1457.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top